Local Inhibition of Liver Fibrosis by Specific Delivery of a Platelet-Derived Growth Factor Kinase Inhibitor to Hepatic Stellate Cells by ( T G et al.
Local Inhibition of Liver Fibrosis by Specific Delivery of a
Platelet-Derived Growth Factor Kinase Inhibitor to Hepatic
Stellate Cells
Teresa Gonzalo,1 Leonie Beljaars, Marja van de Bovenkamp, Kai Temming,
Anne-Miek van Loenen, Catharina Reker-Smit, Dirk K. F. Meijer, Marie Lacombe,
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ABSTRACT
Liver fibrosis is characterized by excessive proliferation and
activation of hepatic stellate cells (HSC), a process in which
platelet-derived growth factor (PDGF) plays an important role.
Inhibition of liver fibrosis via specific delivery of a PDGF kinase
inhibitor to HSC might therefore be an attractive strategy. The
HSC-selective carrier mannose-6-phosphate modified human
serum albumin (M6PHSA) was equipped with a tyrosine kinase
inhibitor, 4-chloro-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-
ylamino)-phenyl]-benzamide (PAP19) (an imatinib derivative),
by means of the platinum-based universal linkage system
(ULS). The antifibrotic activity of PAP19-M6PHSA was evalu-
ated in culture-activated rat HSC and precision-cut liver slices
from fibrotic rats. After 24-h incubation, both free inhibitor
PAP19 and PAP19-M6PHSA showed potent activity, as deter-
mined by quantitative reverse transcription-polymerase chain
reaction analysis of -smooth muscle actin (SMA) and pro-
collagen 1a1. Next, we examined the organ distribution and
antifibrotic activity of PAP19-M6PHSA in bile duct-ligated
(BDL) rats. Male Wistar rats at day 10 after BDL were adminis-
tered a single dose of PAP19-M6PHSA and sacrificed at 2 h, 1
day, or 2 days afterward. The accumulation of PAP19-M6PHSA
in the liver was quantified by high-performance liquid chroma-
tography analysis (30% of the injected dose at 2 h) and de-
tected in the liver by staining of the carrier. Liver drug levels
were sustained at 24 and 48 h after the single dose. Further-
more, PAP19-M6PHSA reduced collagen deposition (Sirius red
staining) and SMA staining of activated HSC at these time
points in comparison with saline-treated rats. We therefore
conclude that delivery of a PDGF-kinase inhibitor to HSC is a
promising technology to attenuate liver fibrogenesis.
Liver fibrosis is a proliferative disease that may be initi-
ated by a variety of factors, including chronic hepatitis, virus
infections, alcohol drinking, and drug abuse. It has been
extensively documented that activated hepatic stellate cells
(HSC) play a fundamental role in the development of liver
fibrosis (Friedman, 1999; Tsukada et al., 2006). During liver
fibrosis, activated HSC proliferate and deposit extracellular
matrix proteins, a process that is driven by an array of
cytokines and growth factors. Among these, platelet-derived
growth factor has been identified as the most potent mitogen
for HSC (Pinzani, 2002). Activated HSC produce PDGF
(Wong et al., 1994) and PDGFR- receptors are highly up-
regulated on the cell surface of hepatic stellate cells during
fibrosis (Bachem et al., 1993; de Bleser et al., 1995; Weiner et
al., 2000).
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Imatinib (STI-571, Gleevec) is used in the treatment of
chronic myelogenous leukemia and gastrointestinal stromal
tumors (von Mehren, 2005). It inhibits several tyrosine ki-
nases that are mutated during cancer development. In addi-
tion, imatinib is a potent inhibitor of PDGF-B receptor
kinase. Consequently, imatinib has been tested for its anti-
fibrotic effect in cultured HSC (Kinnman et al., 2001; Yoshiji
et al., 2005), and it has recently been evaluated in different
animal models of liver fibrosis (Yoshiji et al., 2005; Neef et
al., 2006). The fundamental role that PDGF signaling seems
to play in liver fibrogenesis has made it an attractive thera-
peutic target for the treatment of liver fibrosis (Bataller and
Brenner, 2005).
In the present study, we have investigated whether the
antifibrotic effects of a PDGF tyrosine kinase inhibitor can be
enhanced by local delivery to HSC. Drug targeting can im-
prove the effect of a drug by increasing local concentrations
at the target site and by providing slow local drug release. In
addition, it can prevent side effects in other tissue or organs.
PDGF tyrosine kinase activity plays a role in many physio-
logical processes and its inhibition by imatinib may lead to
side effects such as cardiotoxicity, as reported recently (Ker-
kelä et al., 2006).
To effectuate local delivery within HSC in the liver, we
have developed a new drug-targeting construct, in which a
PDGF kinase inhibitor is coupled to the HSC-directed carrier
protein mannose-6-phosphate-human serum albumin
(M6PHSA). M6PHSA is a well established carrier that binds
to the M6P/insulin-like growth factor-II receptor on HSC and
accumulates rapidly and extensively in the liver of fibrotic
rats (Beljaars et al., 1999). Figure 1 schematically depicts the
structure of the PAP19-M6PHSA conjugate as well as the
structures of imatinib and PAP19, the PDGF kinase inhibitor
used in the present study. Zimmermann et al. (1997) have
evaluated a series of phenyl-amino-pyrimidine (PAP) deriv-
atives closely related to imatinib. Among the evaluated de-
rivatives, PAP19 showed an inhibitory profile similar to ima-
tinib with equivalent potency versus PDGF receptor kinase.
We now have conjugated PAP19 to M6PHSA using a novel
type of platinum linker chemistry called universal linkage
system (ULS). ULS allows stable coupling of drug molecules
to M6PHSA based on the formation of a platinum-ligand
coordination bond (Gonzalo et al., 2006). Application of this
novel linker technology was essential since it seems to be a
straightforward and reliable method for linking PAP19 mol-
ecules to the carrier, allowing high synthesis yields in a
relatively simple approach. In addition, the developed
PAP19-M6PHSA conjugates display a unique behavior of
slow release of drug molecules during a period of days, within
the designated target cells.
In the present study, we describe the development of
PAP19-M6PHSA and its impact on liver fibrogenesis in
vitro and in vivo. Cultured HSC and fibrotic liver slices
were used as in vitro systems to prove the antifibrotic
effect of PAP19 and PAP19-M6PHSA. In addition, PAP19-
M6PHSA was tested in a rat model of liver fibrosis to study
its distribution to the liver and its effects on the develop-
ment of liver fibrosis.
Materials and Methods
Materials
The protein tyrosine kinase inhibitor PAP19 was kindly provided
by György Kéri (Vichem Chemie Research Ltd., Budapest, Hungary).
M6PHSA was prepared as described previously (Gonzalo et al.,
2006). The cis-[Pt(ethylenediamine)nitrate-chloride] (ULS) was pre-
pared as described previously (Gonzalo et al., 2006).
Fig. 1. Structures of the kinase inhibitors and of the
drug targeting conjugate. PAP19-M6PHSA was synthe-
sized by reacting PAP19 via its pyridyl aromatic nitro-
gen to the linker ULS, which was subsequently linked
to M6PHSA. Typically, each PAP19-M6PHSA conjugate
contained eight drug molecules and approximately 30
mannose-6-phosphate groups, which facilitate binding
to activated hepatic stellate cells.
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Synthesis of PAP19-ULS-M6PHSA
PAP19-ULS was synthesized and purified by Kreatech Biotech-
nology (Amsterdam, The Netherlands). In brief, PAP19 [7.2 mol; 3
mg; 10 mg/ml in dimethylformamide (DMF)] was mixed with an
equimolar amount of ULS (7.2 mol, 2.4 mg; 20 mM in dimethylfor-
mamide). The reaction mixture was heated at 37°C for 24 h after
which consumption of the starting material was monitored by ana-
lytical HPLC. An additional amount of ULS was added (0.5 equiva-
lent; 3.6 mol), and the reaction was continued for 48 h at 37°C. The
reaction mixture was concentrated under reduced pressure and dis-
solved in 600 l of methanol. The crude product was purified by
preparative HPLC, and the collected peaks of the main product were
taken to dryness under reduced pressure. The resulting white solid
was treated with water to remove inorganic salts and dried. Yield
was 0.9 mg (20%). Mass spectrometry analysis confirmed the pres-
ence of the 1:1 PAP19-ULS species.
1H NMR of PAP19 (CD3OD). H 2.33 (s, 3H, CH3), 7.26 (d, J 
8.28 Hz, 1H, CCH3CH), 7.37 (m, 2H, CHCl), 7.52 (m, 3H,
N(CH)2CCCH), 7.93 (d, J  8.60 Hz, 2H, CHCHCl), 8.22 (s, 1H,
NHCCHC), 8.47 (d, J  5.23 Hz, 1H, CHNCNH), 8.64 (m, 2H,
CH(CH)2C and CHCHCNH), 9.29 (s, 1H, NCHC) ppm.
1H NMR of PAP19-ULS (CD3OD). H 2.27 (m, 3H, CH3), 2.66 (m,
2H, CH2), 2.74 (m, 2H, CH2), 7.15 (m, 3H, CHCCH3 and CHCl), 7.47
(m, 3H, N(CH)2CCCH), 7.84 (d, J  5.23 Hz, 1H, CHCHCNH), 7.89
(m, 2 H, CHCHCl), 8.39 (d, J  3.95 Hz, 1H, CHNCNH) ppm.
Mass Spectrometry of PAP19-ULS (ESI). Calculated mass:
705 (m/z); detected masses: 706 [M], 688 [M-Cl  OH], 670
[M-Cl  H], 669 [M-Cl  H], 651 [M-Cl-Cl  OH  H].
HPLC Analysis. Separations were performed on a Luna2 C18
column (Phenomenex, Torrance, CA). The mobile phase consisted of
a binary solvent system of 100 mM triethylammonium acetate, pH
5.0/acetonitrile (90:10) (solvent A) and 100 mM triethylammonium
acetate, pH 5.0)/acetonitrile (70:30) (solvent B). The column was
eluted at a flow rate of 1.1 ml/min. Compounds were eluted at a
stepwise gradient (0% B from 0 to 4 min; 0–46% B from 4 to 17 min;
46–100% B from 17 to 19 min; 100% B from 19 to 25 min; 100–0% B
from 25 to 27 min; and 0% B from 27 to 34 min). PAP19 eluted at 21.2
min (60.8% B) and PAP19-ULS eluted at 11.5 min (26.5% B).
PAP19-ULS was conjugated to M6PHSA according to a general
protocol that has been described elsewhere for the synthesis of pen-
toxifylline-ULS-M6PHSA (Gonzalo et al., 2006). In brief, PAP19-
ULS (143 nmol; 1.6 mg that was dissolved in DMF/H2O at 6.7 mg/ml)
was added in 10-fold molar excess to M6PHSA (14.3 nmol; 10 mg,
dissolved in 1 ml of 20 mM Tricine/NaNO3 buffer, pH 8.3) and
reacted overnight at 37°C. The final product was dialyzed against
PBS at 4°C, sterilized by filtration via a 0.2-m filter, and stored at
20°C. Protein content was assessed by the BCA protein assay
(Pierce Chemical, Rockford, IL). PAP19-M6PHSA and M6PHSA
were analyzed by size exclusion chromatography and anion exchange
chromatography as described previously (Beljaars et al., 1999) to
verify that coupling of PAP19-ULS did not alter the properties of the
M6PHSA protein. The amount of PAP19 coupled to M6PHSA was
analyzed by isocratic HPLC after competitive displacement of the
drug by overnight incubation at 80°C with excess of potassium thio-
cyanate (KSCN; 0.5 M in PBS). Elutions were performed on a Waters
system (Waters, Milford, MA) equipped with a 5-m Hypersil BDS
C8 column (250  4.6 mm; ThermoQuest, Runcorn, UK), a thermo-
stated column oven operated at 40°C, and an UV-detector operated
at 269 nm. The mobile phase consisted of acetonitrile/water/triflu-
oroacetic acid (40:60:0.1) at pH 2 and flow rate of 1.0 ml/min with a
sensitivity of 0.01. Retention time for PAP19 was 7 min. Chromato-
grams were also monitored for PAP19-ULS (retention time 5 min) to
confirm that drug release was complete.
Cells
Hepatic stellate cells were isolated and cultured as described
previously (Gonzalo et al., 2006). Cells were split after 3 days, and
they were cultured until day 10 to obtain the activated HSC pheno-
type. Culture-activated HSC were used for the experiments de-
scribed below.
Cell Viability Studies
Activated HSC (10,000 cells/well seeded in 96-well plates; Corning
Life Sciences, Acton, MA) were washed with serum-free medium and
incubated for 24 h in medium supplemented with PAP19-M6PHSA
(0.1 or 1 mg/ml, corresponding to 10 or 100 M PAP19 or ULS linker)
or with free PAP19, free ULS, or unmodified M6PHSA at equimolar
concentrations. To evaluate the sensitivity of HSC to platinum tox-
icity, cells were incubated with cisplatin for 24 h. Cell viability was
assayed by Alamar Blue assay (Serotec, Oxford, UK) according to the
supplier’s instructions.
Effects on Gene Expression
The potential antifibrotic activity of PAP19-M6PHSA and PAP19
was evaluated in cultured HSC and in precision-cut liver slices
prepared of fibrotic rat livers (BDL3 rats, i.e., 3 weeks after bile duct
ligation). Activated HSC were incubated with indicated compounds
for 24 h, after which they were processed for RNA analysis as
described below. In total, four independent experiments were per-
formed in HSC cultures from four different Wistar male rats.
Precision-cut liver slices were prepared as described previously
(Olinga et al., 2001; van de Bovenkamp et al., 2005). After 2 h of
preincubation in Williams’ medium E (Invitrogen, Paisley, Scotland,
UK) supplemented with 25 mM D-glucose and 50 g/ml gentamicin
and saturated with 95% O2, 5% CO2 at 37°C, slices were transferred
into fresh medium and incubated individually in six-well plates with
the indicated compounds for 24 h, after which they were snap-frozen
in liquid nitrogen and stored at 80°C until real-time PCR analysis.
Each measurement was performed on three liver slices from the
same liver, and the experiment was repeated on livers from three
different BDL3 rats.
Animal Experiments
All animal studies were approved by the local committee for care
and use of laboratory animals at Groningen University, and they
were performed according to strict governmental and international
guidelines on animal experimentation. Animals had free access to
tap water and standard laboratory chow, and they were housed
under a 12-h light/dark cycle. All the animals included in these
studies were monitored by analysis of liver/body weight ratio and
biochemical parameters reflecting liver functions, such as serum
bilirubin levels, alanine aminotransferase, and alkaline phosphatase
levels. These analyses were performed at the University Medical
Center Groningen by standard biochemical procedures.
BDL Model
Liver fibrosis was induced in male Wistar rats (250 g; Harlan,
Zeist, The Netherlands) by bile duct ligation as described previously
(Beljaars et al., 1998). Animals were allowed to recover, and then
they were carefully observed until final sacrifice at the end of the
experiments.
Experimental Protocol
At day 10 after BDL, rats received a single intravenous injection of
PAP19-M6PHSA (3.3 mg/kg, corresponding to 150 g of PAP19 per
kg). Control animals were injected with an equivalent volume of the
vehicle (saline, 250 l). Animals were sacrificed 2 h postinjection to
determine initial accumulation of the conjugate within the liver, or
they were sacrificed 24 or 48 h postinjection to determine the effects
of the conjugate on liver fibrosis. Organs were harvested and pro-
cessed for drug analysis, RNA isolation, and immunohistochemical
analysis as described below.
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Analysis of PAP19 Levels in the Liver
Drug levels in the liver were determined according to the HPLC
method described above. In brief, approximately 400 g of liver
tissue was accurately weighed and homogenized in 2 ml of PBS using
an Ultraturrax. One-fourth of the sample was incubated overnight at
80°C with 500 mM KSCN to release PAP19. The drug was extracted
twice with diethyl ether, after which the organic layer was evapo-
rated to dryness and reconstituted in 150 l of mobile phase. Drug
levels were expressed as percentage of the total amount of adminis-
tered PAP19 that had accumulated in the liver.
RNA Isolation and Gene Expression Analysis
Total RNA isolation and synthesis of cDNA was performed accord-
ing to standard procedures. Quantitative real-time reverse tran-
scription-PCR was performed in duplicate on an ABI 7900HT system
(Applied Biosystems, Foster City, CA) using SYBR Green primers.
For each sample, 1 l of cDNA was mixed with 0.4 l of each
gene-specific primer (50 M), 0.8 l of dimethyl sulfoxide, 8.4 l of
water, and 10 l of SYBR Green PCR Master Mix. The housekeeping
gene glyceraldehyde-3-phosphate dehydrogenase was used as a ref-
erence gene and for normalization of the other genes, whereas ultra-
pure water was used as a negative control. Table 1 lists the primers
that have been used to investigate antifibrotic responses. PCR reac-
tions consisted of 40 cycles (denaturation, 15 s at 95°C; annealing,
15 s at 56°C; and extension, 40 s at 72°C). The formation of single
products was confirmed by analyzing the dissociation step at the end
of each PCR reaction. Data were analyzed with the SDS 2.1 software
program (Applied Biosystems). The relative amount of the desig-
nated PCR product was calculated by the comparative threshold
cycle method and referred to control treatment.
Immunohistochemical Analyses
Cryostat sections (4 m) of liver, heart, kidney, lung, and spleen
were acetone-fixed and stained for the presence of the PAP19-
M6PHSA conjugate with an antibody directed against HSA (Cappel
ICN Biomedicals, Zoetermeer, The Netherlands) as described previ-
ously (Beljaars et al., 1998). Expression of PDGF receptor and its
phosphorylation in BDL liver cryosections were investigated by
staining with anti-PDGFR- and anti-phospho-PDGFR- (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA).
The degree of hepatic fibrosis was estimated by staining for colla-
gens using the picrosirius red dye (Sigma, Gillingham, UK). Fibro-
genic myofibroblasts stained with anti-smooth muscle  actin
(SMA; Sigma). Microphotographs were taken with an optic micro-
scope BX40 (Olympus, Tokyo, Japan) connected to a high-resolution
camera (Camedia C-5050 zoom; Olympus) at an original magnifica-
tion of 40. Stainings were quantified by morphometric analysis of
the sections using the ImageJ software package (National Institutes
of Health, Bethesda, MD), and images were captured following au-
tomatic white balance and light intensity equilibration with a 40
magnification objective and digitized as RGB 24-bit. After shading
correction and interactive thresholding, the selected positive pixels
were measured. The positive area was the sum of the area of positive
pixels per liver biopsy. Results were calculated as the average area of
positive pixels per liver biopsy and divided into each group of animal
treatment.
Statistical Analysis
Results are expressed as the mean of at least three independent
experiments  S.D., unless otherwise indicated. Statistical analysis
was performed with an unpaired Student’s t test, and differences
were considered significant at P  0.05.
Results
Synthesis and Characterization of PAP19-M6PHSA
Conjugate. When observing the structure of imatinib or the
related kinase inhibitor PAP19 (Fig. 1), it is clear that their
structures are mainly composed of aromatic rings. Typically,
conjugation reactions for the preparation of a drug-linker
adduct aim at carboxyl, hydroxyl, thiol, or primary amino
groups. Because such functional groups are lacking in ima-
tinib or PAP19, one would need to synthesize a derivatized
molecule, which potentially may alter or destroy the phar-
macological activity of the inhibitor. We therefore pursued a
different strategy in which a novel linker was applied that
binds the drug via a coordinative linkage at the pyridyl
nitrogen of PAP19. HPLC analysis and mass spectrometry
indicated complete derivatization of the drug into the drug-
ULS 1:1 product. The PAP19-ULS adduct was subsequently
conjugated to M6PHSA, and the final high-molecular-weight
product was extensively purified by dialysis, which also re-
moved free PAP19-ULS molecules not linked to the carrier
(HPLC analysis; data not shown). An average of eight
PAP19-ULS molecules was coupled per M6PHSA, as as-
sessed by HPLC after release of the drug from the carrier.
The overall yield of the final reaction step was 84%. Conju-
gation of PAP19 to M6PHSA did not change the charge or
size features of M6PHSA, as determined by anion exchange
chromatography and size-exclusion chromatography, respec-
tively (Fig. 2).
Effects in Cultured Hepatic Stellate Cells and Fi-
brotic Liver Slices. The use of a platinum(II) compound as
a linker may introduce platinum-associated effects in the
drug-targeting preparation. We therefore evaluated HSC vi-
ability in the presence of PAP19-M6PHSA conjugate or its
respective components PAP19, ULS linker, or M6PHSA car-
rier. At high concentrations (100 M), both free cisplatin and
ULS linker displayed toxic effects. PAP19-M6PHSA at equiv-
alent platinum concentrations did not affect HSC viability
(Fig. 3). Neither free drug nor unmodified M6PHSA reduced
HSC viability, although PAP19 at the highest concentration
even increased the number of HSC.
To examine the potential antifibrotic effects of PAP19-
M6PHSA conjugate and nonconjugated PAP19, we investi-
TABLE 1
Primers used to study fibrotic gene expression
Gene Forward Primer Reverse Primer ProductSize
bp
Rat smooth muscle  actin 5-GACACCAGGGAGTGATGGTT-3 5-GTTAGCAAGGTCGGATGCTC-3 202
Rat collagen type 1a1 5-AGCCTGAGCCAGCAGATTGA-3 5-CCAGGTTGCAGCCTTGGTTA-3 145
Rat PDGFR- 5-TGTTCGTGCTATTGCTCCTG-3 5-TCAGCACACTGGAGAAGGTG-3 201
Rat TIMP-1 5-GAGAGCCTCTGTGGATATGT-3 5-CAGCCAGCACTATAGGTCTT-3 334
Rat glyceraldehyde-3-phosphate dehydrogenase 5-CGCTGGTGCTGAGTATGTCG-3 5-CTGTGGTCATGAGCCCTTCC-3 179
Antifibrotic Effects of an HSC-Directed Kinase Inhibitor 859
gated their effects on the expression of fibrosis-related genes
in cultured HSC and fibrotic liver slices. Both PAP19-
M6PHSA and free PAP19 down-regulated the expression of
SMA and collagen 1a1 in cultured HSC (Fig. 4A). In con-
trast, M6PHSA did not affect the expression of these genes in
HSC. The other genes that were examined, PDGF receptor-
and TIMP-1, were not significantly reduced by either treat-
ment.
Precision-cut liver slices were prepared from rats that had
undergone bile duct ligation 3 weeks before, and thus they
encompassed all liver cell types in the context of a fibrotic
extracellular matrix. In agreement with the results in cul-
tured HSC, PAP19-M6PHSA and PAP19 showed pronounced
reductions in the expression of SMA and collagen 1a1 (Fig.
4B). In addition, PDGFR- (PAP19-M6PHSA and PAP19)
and TIMP-1 (PAP19) gene levels were inhibited significantly
Fig. 2. Characteristics of PAP19-M6PHSA drug-targeting conjugate. A,
Mono Q anion exchange chromatography confirmed that the charge of the
protein was not affected after coupling of PAP19-ULS to the carrier. Both
M6PHSA and PAP19-M6PHSA eluted at a later retention time than
unmodified HSA due to the negatively charged mannose-6-phosphate
groups. B, size exclusion chromatography showed the monomeric compo-
sition of PAP19-M6PHSA. Notice the similar elution profiles of M6PHSA
and PAP19-M6PHSA.
Fig. 3. Activated HSC incubated with PAP19-M6PHSA. Effect of PAP19-
M6PHSA and drug, linker and carrier on HSC cell viability, as deter-
mined by Alamar Blue assay. Cultured HSC were incubated for 24 h with
the compounds. Indicated concentrations reflect the platinum content of
the tested compounds or equivalent amounts of PAP19 or M6PHSA (,
P  0.05).
Fig. 4. Effects of PAP19 and PAP19-M6PHSA on the expression of
fibrotic genes. Activated HSC (A) and precision-cut slices (B) from BDL
rats were incubated for 24 h with PAP19 or PAP19-M6PHSA (both at 10
M drug). M6PHSA was tested in an equivalent concentration of carrier
(0.1 mg/ml). Gene expressions levels were normalized to the expression
levels in control HSC or slices (, P  0.05).
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in slices, whereas those genes were not affected in cultured
HSC. Furthermore, M6PHSA carrier showed inhibitory ef-
fects on some of the investigated genes, although TIMP-1
expression was enhanced by M6PHSA. Differences between
PAP19-M6PHSA were significant for SMA and collagen
1a1. These results encouraged us to evaluate PAP19-
M6PHSA in an animal model of liver fibrosis.
Animal Studies. To demonstrate that PAP19-M6PHSA
was capable of homing to the fibrotic liver and that the
compound is capable of inhibiting early stages of fibrogen-
esis, BDL rats at day 10 after ligation of the bile were treated
with a single dose of the product. In the rat BDL model, HSC
activation associated with PDGF receptor expression and
downstream signaling is prominent at this day (Neef et al.,
2006). In addition, the expression of the M6P/insulin-like
growth factor-II receptor, which recognizes M6PHSA, is also
increased at day 10 after BDL (Greupink et al., 2006a).
Table 2 shows the characteristics of the BDL rats included
in the studies. The animals were treated with a relatively low
dose of PAP19-M6PHSA (1 mg of conjugate/animal), which
corresponds to 150 g/kg conjugated drug. Administration of
PAP19-M6PHSA did not affect the body weight of the rats,
nor did it change the biochemical parameters that were an-
alyzed.
Distribution of PAP19-M6PHSA in Fibrotic Rats. Pre-
vious studies in our laboratory have demonstrated that
M6PHSA extensively binds to activated HSC in the fibrotic
liver (Beljaars et al., 1999). Typically, about 60% of the in-
jected carrier accumulated in the fibrotic liver already within
10 min after administration (e.g., Gonzalo et al., 2006). In the
present study, PAP19-M6PHSA organ distribution was in-
vestigated at a later time point, 2 h after administration of
the product, to allow for a more complete distribution of the
conjugate (Fig. 5). PAP19-M6PHSA was detectable in the
liver in a nonparenchymal staining pattern. Although double
immunostaining to detect colocalization with HSC failed due
to the faint staining (data not shown), these results suggest
that PAP19-M6PHSA homed to the liver in a similar manner
as other HSC-selective conjugates. PAP19-M6PHSA was un-
detectable in other organs, such as heart, kidney, lung, and
spleen (Fig. 5, C–F).
We furthermore quantified the accumulation of PAP19-
M6PHSA in the liver by assaying PAP19 levels by HPLC. As
can be observed in Fig. 6, 30% of the injected dose had been
accumulated in the liver after 2 h, and these drug levels
persisted up to the last time point at 48 h.
Effects of PAP19-M6PHSA in Fibrotic Rats. Antifi-
brotic effects of PAP19-M6PHSA were studied at the latter
two time points of the study, 24 and 48 h after administration
of the conjugate. First, we investigated whether PAP19-
M6PHSA affected fibrotic gene expression in a similar ap-
proach as described above for cultured HSC and precision-cut
slices. We did not observe changes in the expression of fibro-
sis reporter genes (data not shown). Immunohistochemical
staining of fibrotic markers, however, clearly indicated the
establishment of fibrosis and the pharmacological activity of
PAP19-M6PHSA. Sirius red staining for collagen showed a
continuous increment in deposited extracellular matrix com-
ponents from day 10 to 12 after bile duct ligation (Fig. 7A).
Treatment with a single dose of PAP19-M6PHSA signifi-
cantly attenuated collagen deposition at both 24 and 48 h
TABLE 2
Dose regimens, animal data, and biochemical parameters from PAP19-M6PHSA single injection study
Data are shown as mean  S.D.
BDL Day 10 
Saline
BDL Day 11 
Saline
BDL Day 12 
Saline
BDL Day 10 
PAP19-M6PHSA
BDL Day 11 
PAP19-M6PHSA
BDL Day 12 
PAP19-M6PHSA
No. of rats 4 4 4 2 4 4
Body wt (g) 250.2  46.7 311.2  14.7 273.4  16.4 280.7  10.1 301.4  14.1 306.4  13.5
Liver/body wt ratio (g/g) 0.055  0.009 0.062  0.007 0.065  0.004 0.061  0.002 0.060  0.006 0.065  0.009
Dose Saline Saline Saline 3.3 mg/kg 3.3 mg/kg 3.3 mg/kg
Bilirubin (mol/l) 183.7  35.8 178.0  48.2 228.5  18.7 252.3  55.9 136.0  10.0 183.5  27.9
Alanine amino transferase
(U/l)
86.3  30.9 79.8  46.1 79.3  11.2 96.5  4.9 72.7  10.6 81.0  17.0
Alkaline phosphatase (U/l) 391.2  46.4 476.0  162.6 358.3  234.1 458.0  11.2 426.0  101.3 511.3  121.4
Fig. 5. Organ distribution of PAP19-M6PHSA in BDL rats. Immuno-
staining with anti-HSA was performed on tissue sections from saline-
treated BDL rats (A) or rats treated with PAP19-M6PHSA that had been
sacrificed 2 h after single-dose administration. A, liver of saline treated
BDL rat. B, liver of PAP19-M6PHSA-treated BDL rat. C to F, heart,
kidney, lung, and spleen of PAP19-M6PHSA treated BDL rat. Magnifi-
cation, 20.
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after administration. Apart from reduced staining intensity,
the antifibrotic effect of PAP19-M6PHSA was illustrated by a
reduced portal-portal bridging in fibrotic areas (Fig. 7B).
Likewise, treatment with PAP19-M6PHSA significantly at-
tenuated the SMA-stained area in the liver at both 24 and
48 h after single-dose treatment (Fig. 8).
Discussion
Liver fibrosis is in principle a reversible process in which
the stellate cells have been identified as the key fibrogenic
cells (Friedman, 2003). PDGF is the most potent mitogen for
HSC in vitro, and it plays an important role in the transfor-
mation of HSC into myofibroblast-like cells in vivo (Pinzani
et al., 1994). Targeting the PDGF signaling cascade therefore
represents a promising antifibrotic approach. Several recent
studies have described the antifibrogenic properties of the
kinase inhibitor imatinib in different models of fibrotic dis-
ease (Lassila et al., 2005; Wang et al., 2005; Yoshiji et al.,
2005). In contrast, concerns have been raised in relation to
the effectiveness of imatinib as an antifibrogenic drug (Neef
et al., 2006; Vittal et al., 2007), especially in later stages of
liver fibrosis. In the present study, the new product PAP19-
M6PHSA was designed to effectively and specifically deliver
an imatinib-related kinase inhibitor to HSC, to improve its
antifibrotic properties. We demonstrate the antifibrogenic
effects of PAP19-M6PHSA in two different validated in vitro
systems. Furthermore, we show the sustained delivery of the
drug within the liver as well as its potential activity in rats
with liver fibrosis.
PAP19 is a potent inhibitor of PDGR-kinase with an IC50 of
10 nM (Zimmermann et al., 1997). We confirmed the antifi-
brotic potential of PAP19 by incubating culture-activated
HSC and BDL liver slices with the drug. Our results with
PAP19 are in good agreement with previous studies in which
imatinib was tested for its activity in HSC (Yoshiji et al.,
2005) or liver slices (van de Bovenkamp et al., 2006). Ima-
tinib dose-dependently inhibited fibrotic gene expression in
slices, reaching 70 to 80% inhibition of collagen 1a1 and
SMA at 10 M (van de Bovenkamp et al., 2006). No toxicity
of imatinib was observed in fibrotic slices. In PDGF-stimu-
lated HSC, 10 M imatinib blunted the expression of SMA
and 2-(I)-procollagen in addition to an almost complete in-
hibition of PDGF-induced proliferation and migration (Yo-
shiji et al., 2005). We did not add external PDGF to our
experiments, but it has been reported that the growth factor
is synthesized in situ by activated HSC in culture or in slices
(Pinzani, 2002). We also found that PAP19 reduced
PDGFR- and TIMP-1 expression in BDL slices. TIMP-1
expression is increased during liver fibrosis, and it plays an
important role in liver fibrogenesis by modulating extracel-
lular matrix remodeling (Iredale et al., 1998). Taken to-
gether, these data support our hypothesis that PAP19 is a
proper candidate for HSC-directed drug delivery.
PAP19-M6PHSA potently inhibited fibrotic gene expres-
sion in both HSC and fibrotic liver slices. These results are
remarkable taking into account that carrier-bound drug most
probably should be released from the carrier to become ac-
tive. First, the attachment of PAP19 to ULS and subse-
quently to the carrier will prevent the pharmacological ac-
tivity of PAP19, because the active site of the drug is blocked
by the linker. Intracellular release of the compound will
revert PAP19-M6PHSA to the active kinase inhibitor. Sec-
Fig. 6. Liver drug levels after single-dose treatment with PAP19-
M6PHSA. Liver homogenate was treated as described under Materials
and Methods to liberate conjugated PAP19 from the linker, followed by
HPLC analysis of the parent drug. Drug levels were expressed as per-
centage of the injected dose by correcting for liver weights and adminis-
tered dose.
Fig. 7. Effect of single-dose administration of PAP19-M6PHSA on the
deposition of collagen in the liver of BDL rats. A, quantification of the
area with Sirius red staining in rat liver specimens (n  25; mean  S.D.;
, P  0.05 versus saline-treated group at same day). Day 10, 11, and 12
correspond to 2, 24, and 48 h after administration of compounds, respec-
tively. B, representative liver sections processed for Sirius red collagen
staining. Rats receiving saline (left) showed a marked deposition of col-
lagen, as assessed with Sirius red, which colocalized with areas with
active fibrogenesis. Rats treated with PAP19-M6PHSA (right) showed
attenuated liver fibrosis development. Magnification, 40.
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ond, drug-M6PHSA conjugates cannot diffuse across cell
membranes, but they will enter cells by receptor-mediated
endocytosis, followed by lysosomal routing (Beljaars et al.,
2001). Since the kinase domain of the PDGF receptor is
located in the cytosol, the conjugate will not end up in the
same intracellular compartment as the pharmacological tar-
get of PAP19. We postulate that the conjugate is degraded
efficiently in the lysosomes of HSC and that during this
process drug will be released from the carrier. A possible
mechanism by which drug release can take place is compet-
itive displacement by glutathione or other endogenous com-
pounds that can coordinate to platinum (Gonzalo et al., 2006;
Prakash et al., 2006; Temming et al., 2006a,b).
Rapid degradation of the conjugate within the lysosomal
compartment of target cells also explains the faint staining
of PAP19-M6PHSA in the liver after its administration to
BDL rats. To allow for a more complete accumulation of
the conjugate within the liver, we sacrificed the animals at
a rather late time point (2 h) compared with other studies
from our group in which staining was performed 10 to 20
min after administration (Gonzalo et al., 2006; Greupink
et al., 2006b; Hagens et al., 2007). Most probably, this
prolonged period allowed for the uptake and degradation of
the carrier by target cells, whereas the majority of the
compound was bound extracellularly or in the endosomes
at the 10- to 20-min time point. Thus, anti-HSA staining
resulted in poor immunodetection of the PAP19-M6PHSA
conjugate. However, the analysis of the coupled drug by
HPLC clearly showed the efficient accumulation of PAP19-
M6PHSA in the liver. Furthermore, the persistence of high
drug levels even at 2 days after its administration denotes
that PAP19 is retained within the fibrotic liver. This result
is in good agreement with the results of another drug-ULS
construct aimed at the kidney, which could be detected up
to 3 days after single dosing (Prakash et al., 2006).
Whether the released PAP19 molecules will be retained
within HSC or redistribute to other cell types within the
liver is presently unknown. Although one may argue that
redistribution of the delivered drug is unfavorable, it may
also help in reaching profibrogenic liver cell types such as
peribiliary fibroblasts. Highest drug levels can be ex-
pected, however, in target cells that have accumulated and
internalized the conjugate. It is noteworthy that the drug
delivery strategy greatly lowered the systemic distribution
of imatinib, because a much lower dose was administered
than commonly applied for liver fibrosis treatment, 150
g/kg as a single dose versus 5 to 20 mg/kg daily, respec-
tively. This lower dose was furthermore accumulated pref-
erentially within the fibrotic liver. Thus, potential side
effects of imatinib in nonfibrotic tissues will be avoided,
which seems relevant in view of the reported cardiotoxicity
of imatinib (Kerkelä et al., 2006).
Eventually, released PAP19 should effectuate a sustained
blockade of PDGF kinase activity within the fibrotic liver.
Staining for phosphorylated PDGF receptor in untreated
BDL rats at day 10 after ligation was, however, scattered,
and it did not match the pattern of total PDGF receptor (data
not shown). This may relate to a technical problem as the
commercially available antibodies were not reported for im-
munostaining of fibrotic tissues. Yoshiji et al. (2005) have
reported on the capability of imatinib to inhibit PDGF recep-
tor phosphorylation in HSC, and the anti-PDGF kinase activity
of PAP19 has been well documented (Zimmermann et al., 1997).
Because pharmacological activity of PAP19-M6PHSA is ob-
served in HSC and fibrotic slices, it is feasible that kinase
inhibition has occurred in the cells that have accumulated
PAP19-M6PHSA. Although this event could not be directly
demonstrated, the pharmacological effects of the construct
found in vivo are in accordance with this hypothesis.
After single administration, PAP19-M6PHSA markedly re-
duced collagen deposition together with a suppression of
SMA-positive cells, which reflects a reduction in the num-
ber of activated HSC (Olaso and Friedman, 1998). In contrast
to the effects on protein expression of fibrotic markers,
PAP19-M6PHSA administration did not affect the gene ex-
pression of such markers in BDL rats. This discrepancy ei-
ther reflects different sensitivity of the assays, or it corre-
sponds to a greater reduction of collagen and SMA at the
protein level than at gene expression level. This divergence
has been described previously in experiments investigating
the inhibition of hepatic fibrosis (Yata et al., 2002), and it
might be due to post-transcriptional regulation of collagen
expression in cultured HSC (Stefanovic et al., 1997).
Several other approaches for blockade of the PDGF sig-
Fig. 8. Effect of single-dose administration of PAP19-M6PHSA on the
accumulation of myofibroblasts and activated HSC in BDL rat livers, as
assessed by SMA expression. A, quantification of the area with SMA
staining in rat liver specimens (n  25; mean  S.D.; , P  0.05 versus
saline-treated BDL group at same day). Day 10, 11, and 12 correspond to
2, 24, and 48 h after administration of compounds, respectively. B, rep-
resentative liver sections processed for SMA immunohistochemistry.
Rats receiving saline (left) showed a marked accumulation of SMA-
positive cells, which colocalized with areas with active fibrogenesis. Rats
treated with PAP19-M6PHSA (right) showed less SMA-positive cells.
Magnification, 40.
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naling cascade have been investigated as a strategy to
block liver fibrosis. Some studies showed that monoclonal
antibodies directed against the extracellular domain of the
PDGF receptor can prevent binding of the PDGF ligand,
thereby inhibiting mitogenic signaling (Heldin, 1997;
Shulman et al., 1997). In a different strategy, Borkham-
Kamphorst et al. (2004) produced a soluble PDGF receptor
that was capable of reducing extracellular matrix deposi-
tion in the BDL model after daily administration for 14
days. Consistent with this, short-term treatment with ima-
tinib in the BDL model caused a marked reduction in HSC
proliferation (Kinnman et al., 2001). According to Neef and
colleagues, the effect of imatinib is limited to the early
phase of fibrogenesis, due to the lack of efficiency in ad-
vanced liver injury, i.e., 3 to 4 weeks after BDL (Neef et al.,
2006). In contrast to this latter observation, another study
reported a pronounced inhibition of SMA-positive fibro-
blast and expression of fibrosis markers after 8 weeks of
imatinib administration to fibrotic rats (Yoshiji et al.,
2005). These authors studied the effect of imatinib in the
pig serum-induced model of liver fibrosis, which is charac-
terized by a slow progression of fibrogenesis, resembling
the human situation. Thus, it might be a relevant therapy
in patients with early stages of liver fibrosis.
In conclusion, we have evaluated a new strategy for local
delivery of a PDGF kinase inhibitor to the fibrotic liver.
Our strategy differs completely from the aforementioned
studies in which the free drug imatinib is used. We used a
carrier molecule that is internalized by target HSC, after
which the kinase inhibitor is released inside the cells. The
delivered kinase inhibitor produced a significant effect on
the fibrotic process 24 to 48 h after its administration to
BDL rats. These results illustrate the potential of using
PAP19-M6PHSA as a cell-specific drug that may effec-
tively lead to reduced activation of HSC and consequently
may reduce liver fibrosis.
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